Abstract:Major Depressive Disorder (MDD) is a common, frequently chronic condition characterized by substantial molecular alterations and pathway dysregulations. Single metabolite and targeted metabolomics platforms have revealed several metabolic alterations in depression, including energy metabolism, neurotransmission, and lipid metabolism. More comprehensive coverage of the metabolome is needed to further specify metabolic dysregulations in depression and reveal previously untargeted mechanisms. Here, we measured 820 metabolites using the metabolome-wide Metabolon platform in 2770 subjects from a large Dutch clinical cohort with extensive clinical phenotyping (1101 current MDD, 868 remitted MDD, 801 healthy controls) at baseline, which were repeated in 1805 subjects at 6-year follow up (327 current MDD, 1045 remitted MDD, 433 healthy controls). MDD diagnosis was based on DSM-IV psychiatric interviews. Depression severity was measured with the Inventory of Depressive Symptomatology Self-report. Associations between metabolites and MDD status and depression severity were assessed at baseline and at 6-year follow-up. At baseline, 139 and 126 metabolites were associated with current MDD status and depression severity, respectively, with 79 overlapping metabolites. Adding body mass index and lipid-lowering medication to the models changed results only marginally. Among the overlapping metabolites, 34 were confirmed in internal replication analyses using 6-year follow-up data. Downregulated metabolites were enriched with long-chain monounsaturated ( P = 6.7e−07) and saturated ( P = 3.2e−05) fatty acids; upregulated metabolites were enriched with lysophospholipids ( P = 3.4e−4). Mendelian randomization analyses using genetic instruments for metabolites ( N = 14,000) and MDD ( N = 800,000) showed that genetically predicted higher levels of the lysophospholipid 1-linoleoyl-GPE (18:2) were associated with greater risk of depression. The identified metabolome-wide profile of depression indicated altered lipid metabolism with downregulation of long-chain fatty acids and upregulation of lysophospholipids, for which causal involvement was suggested using genetic tools. This metabolomics signature offers a window on depression pathophysiology and a potential access point for the development of novel therapeutic approaches.

Disturbances of Phosphatidylcholines Metabolism in Major Depressive Disorder.

Plasma Disturbance of Phospholipid Metabolism in Major Depressive Disorder by Integration of Proteomics and Metabolomics

Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression

Metabolomic analysis reveals metabolic disturbances in the prefrontal cortex of the lipopolysaccharide-induced mouse model of depression

Plasma metabolites were associated with spatial working memory in major depressive disorder

Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder

Plasma Metabolomics Profiling of Metabolic Pathways Affected by Major Depressive Disorder

Metabolite Signature for Diagnosing Major Depressive Disorder in Peripheral Blood Mononuclear Cells

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents

Alteration of Glycerophospholipid Metabolism in Hippocampus of Post-stroke Depression Rats

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia.

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

Abnormal Functional Connectivity Within the Prefrontal Cortex is Associated with Multiple Plasma Lipid Species in Major Depressive Disorder.

Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis

The metabolome-wide signature of major depressive disorder

Proteomic Analysis Reveals Energy Metabolic Dysfunction and Neurogenesis in the Prefrontal Cortex of A Lipopolysaccharide-Induced Mouse Model of Depression

Tissue-Specific Oxysterols As Predictors of Antidepressant (escitalopram) Treatment Response in Patients with Major Depressive Disorder

Combinatorial panel with endophenotypes from multilevel information of diffusion tensor imaging and lipid profile as predictors for depression

Elevated SCN11A Concentrations Associated with Lower Serum Lipid Levels in Patients with Major Depressive Disorder